Literature DB >> 3121822

Immunology of premalignant and malignant conditions of the oral cavity. II. Circulating immune complexes.

P Balaram1, M R Pillai, T Abraham.   

Abstract

Quantitation of circulating immune complexes (CIC) levels was established in patients with oral cancer and oral precancerous lesions. The levels were compared with that in normal controls and chronic chewers of betel quid with no signs of any disease. Both patients with oral cancer and oral precancerous lesions had elevated CIC when compared to both the control groups. The most interesting observations were (a) the CIC levels in the chewing controls were significantly raised when compared to normal controls; and (b) the CIC levels in the patients with premalignant lesions were elevated almost to the same levels as in the oral cancer patients.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3121822     DOI: 10.1111/j.1600-0714.1987.tb02070.x

Source DB:  PubMed          Journal:  J Oral Pathol        ISSN: 0300-9777


  4 in total

1.  Augmentation of T-cell immune responses and signal transduction proteins in oral cancer patients: potential for IL-2-mediated immunotherapy.

Authors:  Vino T Cheriyan; Cessal Thomas; Prabha Balaram
Journal:  J Cancer Res Clin Oncol       Date:  2011-08-02       Impact factor: 4.553

2.  Interferon and interleukin-2 induced spontaneous cell-mediated cytotoxicity: a preliminary evaluation.

Authors:  P Balaram; M R Pillai; T Abraham; K R Nalinakumari; G Meenattoor; S Kannan; N K Hareendran; M K Nair
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

3.  PTMA, a new identified autoantigen for oral submucous fibrosis, regulates oral submucous fibroblast proliferation and extracellular matrix.

Authors:  Jie Wang; Jialing You; Lekai Wang; Huimin Wang; Tian Tian; Wenjin Wang; Lina Jia; Canhua Jiang
Journal:  Oncotarget       Date:  2017-08-24

4.  The protective effect of the Vacha rhizome extract on chronic stress-induced immunodeficiency in rat.

Authors:  H N Sarjan; S Divyashree; H N Yajurvedi
Journal:  Pharm Biol       Date:  2017-12       Impact factor: 3.503

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.